Rein Therapeutics LTI-03 Phase 2 Trial Enrolls 8 Patients for Idiopathic Pulmonary Fibrosis Treatment

Key Takeaways

• Rein Therapeutics has enrolled 8 patients in its Phase 2 RENEW study of LTI-03 for idiopathic pulmonary fibrosis
• Clinical trial sites are now active across three countries: United States, Australia, and Poland, with expansion planned
• Patient enrollment began in March 2026 and continues on a regular basis with additional participants expected soon

---

AUSTIN, Texas - Rein Therapeutics (NASDAQ: RNTX) announced progress in patient enrollment for its Phase 2 RENEW clinical trial evaluating LTI-03 as a treatment for idiopathic pulmonary fibrosis (IPF), a rare and progressive lung disease.

The biopharmaceutical company reported that 8 patients have been enrolled in the study, with enrollment momentum building across an expanding network of international clinical sites. The trial launched patient recruitment in March 2026 and has maintained steady enrollment progress.

Global Trial Expansion Underway

The RENEW study currently operates clinical trial sites in three countries: the United States, Australia, and Poland. Rein Therapeutics indicated that additional countries are expected to join the trial network in the near term, potentially accelerating patient recruitment for this critical rare disease study.

Idiopathic pulmonary fibrosis affects approximately 100,000 people in the United States and represents a significant unmet medical need. The progressive scarring of lung tissue characteristic of IPF leads to declining lung function and limited treatment options for patients.

LTI-03 Development Program

LTI-03 represents Rein Therapeutics’ investigational approach to addressing IPF through a novel mechanism of action. The Phase 2 RENEW study aims to evaluate the safety and efficacy of LTI-03 in patients with this challenging condition.

The company’s ability to establish clinical sites across multiple continents demonstrates the global interest in advancing IPF treatment options. International trial networks often enable faster patient recruitment and broader data collection, potentially accelerating the path to regulatory review.

Market Impact and Timeline

With regular patient additions expected and site expansion planned, Rein Therapeutics appears positioned to maintain enrollment momentum throughout 2026. The company has not disclosed specific enrollment targets or anticipated completion timelines for the Phase 2 study.

The IPF treatment market continues to attract significant pharmaceutical investment due to limited current therapies and the serious nature of the disease progression.

---

Frequently Asked Questions

What is LTI-03 and how does it treat idiopathic pulmonary fibrosis?

LTI-03 is Rein Therapeutics’ investigational drug candidate for treating idiopathic pulmonary fibrosis (IPF). The company has not disclosed the specific mechanism of action, but it’s currently being evaluated in a Phase 2 clinical trial called RENEW to assess its safety and efficacy in IPF patients.

When will LTI-03 be available to patients with IPF?

LTI-03 is still in Phase 2 clinical trials, which means it’s several years away from potential market availability. The drug would need to complete Phase 2 testing, advance to Phase 3 trials, and receive regulatory approval before becoming available to patients outside of clinical studies.

How many patients will be enrolled in the RENEW study?

Rein Therapeutics has not disclosed the target enrollment number for the Phase 2 RENEW study. Currently, 8 patients are enrolled with additional participants expected as the company expands to more clinical sites internationally.